<DOC>
	<DOCNO>NCT00509821</DOCNO>
	<brief_summary>The purpose protocol induce novel radiochemotherapy enzastaurin first-line treatment regimen glioblastoma : Patients active , unmethylated MGMT promoter treat enzastaurin , concomitant , radiotherapy determine safety PFS 6 month ( PFS-6 ) phase II .</brief_summary>
	<brief_title>Enzastaurin Before Concomitant With Radiation , Followed Enzastaurin Patients With Newly Diagnosed Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>Present newly diagnose histologically proven supratentorial GBM . Demonstration unmethylated MGMTpromotor Patients must sign informed consent document . Patients must least 18 year age . Estimated life expectancy least 12 week Tumor tissue specimen ( paraffinembedded and/or frozen ) GBM surgery biopsy must available central pathology review exploratory analysis PKCbeta target ( example , GSK3beta ) . Disease evaluate GdMRI ( magnetic resonance imaging ) within 72 hour postoperatively Interval great equal 2 less equal 4 week since surgery biopsy ECOG Performance Status less equal 2 Adequate organ function include follow : adequate bone marrow reserve : white blood cell ( WBC ) count great equal 3.0 X 109/L , absolute neutrophil count ( ANC ) great equal 1.5 X 109/L , platelet count great equal 75.0 X 109/L , hemoglobin great equal 10.0 g/dL ( great equal 6.2 mmol/L ) . Hepatic : bilirubin le equal 1.5 time upper limit normal ( X ULN ) , alkaline phosphatase ( ALP ) , aspartate transaminase ( AST ) , alanine transaminase ( ALT ) less equal 2.5 X ULN , less equal 5 X ULN liver metastases Renal : serum creatinine less equal 1.5 X ULN Blood clotting : prothrombin time ( PT ) partial thromboplastin time ( PTT ) within normal limit Patients must discontinue use enzymeinducing antiepileptic drug ( EIAEDs ) great equal 14 day prior study enrollment . The investigator may prescribe nonEIAEDs . Patients must begin EIAED therapy study allow remain study . Clinically normal cardiac function without history ischemic heart disease past 6 month normal 12lead electrocardiogram ( ECG ) ; history stroke Have prior malignancy ( glioblastoma , adequately treat carcinoma situ cervix , nonmelanoma skin cancer ) , unless prior malignancy diagnose definitively treat least 5 year previously subsequent evidence recurrence Unable undergo Gd MRI Prior chemotherapy within last 5 year Prior chemotherapy brain tumor Prior radiotherapy head Are unable discontinue use carbamazepine , phenobarbital , phenytoin History coagulation disorder associate bleeding , recurrent thrombotic event Are receive concurrent administration anticoagulant therapy Placement GliadelÂ® wafer surgery Have serious concomitant systemic disorder ( example , active infection include HIV , cardiac disease ) patient pregnant , anticipate become pregnant within 6 month study participation , currently breastfeed Have receive treatment within last 30 day drug receive regulatory approval indication time study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>